AstraZeneca (LON:AZN) had its price target increased by research analysts at HSBC from GBX 4,340 ($58.41) to GBX 4,380 ($58.95) in a report issued on Thursday, November 16th. The brokerage currently has a “reduce” rating on the biopharmaceutical company’s stock. HSBC’s target price suggests a potential downside of 7.69% from the stock’s current price.
Other analysts also recently issued reports about the company. Credit Suisse Group decreased their price target on AstraZeneca from GBX 5,000 ($67.29) to GBX 4,700 ($63.26) and set a “neutral” rating for the company in a research report on Friday, July 28th. Shore Capital reissued a “hold” rating on shares of AstraZeneca in a report on Wednesday, August 2nd. Goldman Sachs Group set a GBX 3,900 ($52.49) price objective on AstraZeneca and gave the company a “sell” rating in a report on Wednesday, August 2nd. Investec raised their price target on AstraZeneca from GBX 4,900 ($65.95) to GBX 5,500 ($74.02) and gave the stock a “buy” rating in a report on Monday, November 6th. Finally, Barclays reaffirmed an “overweight” rating and issued a GBX 5,500 ($74.02) price target on shares of AstraZeneca in a report on Tuesday, August 1st. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. AstraZeneca has a consensus rating of “Hold” and a consensus price target of GBX 5,164.45 ($69.51).
Shares of AstraZeneca (LON:AZN) traded down GBX 22 ($0.30) on Thursday, hitting GBX 4,745 ($63.86). The company had a trading volume of 1,823,066 shares, compared to its average volume of 2,180,000. AstraZeneca has a one year low of GBX 3,996 ($53.78) and a one year high of GBX 5,520 ($74.29).
TRADEMARK VIOLATION WARNING: This story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/04/hsbc-holdings-plc-raises-astrazeneca-plc-azn-price-target-to-gbx-4380.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.